Artelo Biosciences, Inc. (ARTL) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Artelo Biosciences, Inc.
Address
505 Lomas Santa Fe
Solana Beach, CA 92075
United States of America (the)
Phone
858 925 7049
Website
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
June 21, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Gregory D. Gorgas | President, Chief Executive Officer, Secretary & Director | 876,923 | 1963 |
| Mark E. Spring | Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer | 225,980 | 1959 |
| Andrew Yates | Senior Vice President & Chief Scientific Officer | 0 | N/A |
| Steven D. Reich | Chief Medical Officer | 0 | 1946 |
| Jason H. Baybutt | Senior Vice President of Finance | 0 | 1972 |
Description
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
